Statistiche di base
| CIK | 1780097 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Baudax Bio, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Baudax Bio, Inc. |
|
| February 14, 2024 |
US07160F4046 / BAUDAX BIO INC / BLACK HORSE CAPITAL LP Passive Investment SC 13G/A 1 baudax13ga1-02142024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Baudax Bio Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 07160F404 (CUSIP Number) Decembe |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Baudax Bio, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 07160F404 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 Baudax Bio, Inc. |
|
| November 22, 2023 |
Up to 15,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274349 Prospectus Supplement (to prospectus dated September 25, 2023) Up to 15,000,000 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement the information contained in the prospectus dated September 25, 2023 (as may be supplemented or amended from time to time, the “Prospectus |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended: September 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-39101 Baudax Bio, Inc. (Exact name of registrant as specif |
|
| November 15, 2023 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (CHECK ONE): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR Commission File Number: 001-39101 For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transitio |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Baudax Bio, Inc. |
|
| October 25, 2023 |
Exhibit 16.1 October 25, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated October 25, 2023 of Baudax Bio, Inc. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the registrant contained in Item 4.01. Sincerely, |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Baudax Bio, Inc. |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 Baudax Bio, Inc. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 6, 2023 |
October 2023 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Baudax Bio, Inc. |
|
| September 29, 2023 |
Exhibit 99.1 Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 Baudax Bio, Inc. |
|
| September 21, 2023 |
Baudax Bio, Inc. 490 Lapp Rd. Malvern, Pennsylvania 19355 September 21, 2023 Baudax Bio, Inc. 490 Lapp Rd. Malvern, Pennsylvania 19355 September 21, 2023 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Baudax Bio, Inc. Registration Statement on Form S-3 (File No. 333-272994) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effect |
|
| September 21, 2023 |
Baudax Bio, Inc. 490 Lapp Rd. Malvern, Pennsylvania 19355 September 21, 2023 Baudax Bio, Inc. 490 Lapp Rd. Malvern, Pennsylvania 19355 September 21, 2023 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Baudax Bio, Inc. Registration Statement on Form S-1 (File No. 333-274349) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the eff |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| September 7, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 5, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Baudax Bio, Inc. |
|
| September 5, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Baudax Bio, Inc. |
|
| September 5, 2023 |
EX-10.1 Exhibit 10.1 AMENDMENT NO. 7 TO CREDIT AGREEMENT This Amendment No. 7 to Credit Agreement (this “Amendment”) dated as of August 31, 2023, is among Baudax Bio, Inc., a Pennsylvania corporation (“Borrower”), Baudax Bio N.A. LLC, a Delaware limited liability company (“Baudax LLC”), Baudax Bio Limited, a private company incorporated under the laws of Ireland limited by shares having company nu |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 S-1 Table of Contents As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Baudax Bio, Inc. |
|
| August 25, 2023 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 25, 2023 |
Purchase Agreement, dated August 23, 2023, between Baudax Bio, Inc. and Alumni Capital LP. Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of August 23, 2023, by and between BAUDAX BIO, INC., a Pennsylvania corporation (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes t |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 Baudax Bio, Inc. |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 Baudax Bio, Inc. |
|
| August 24, 2023 |
Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock EX-3.1 Exhibit 3.1 BAUDAX BIO, INC. CERTIFICATE OF DESIGNATION OF SERIES C PREFERRED STOCK OF BAUDAX BIO, INC. AUGUST 24, 2023 Baudax Bio, Inc., a corporation organized and existing under the laws of the Commonwealth of Pennsylvania (the “Corporation”), in accordance with the provisions of 1522(b), (c), and (d) of the Pennsylvania Business Corporation Law of 1988, as amended (the “PBCL”), does her |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-A For Registration of Certain Classes of Securities Pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934 Baudax Bio, Inc. |
|
| August 24, 2023 |
Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock. Exhibit 3.1 BAUDAX BIO, INC. CERTIFICATE OF DESIGNATION OF SERIES C PREFERRED STOCK OF BAUDAX BIO, INC. AUGUST 24, 2023 Baudax Bio, Inc., a corporation organized and existing under the laws of the Commonwealth of Pennsylvania (the “Corporation”), in accordance with the provisions of 1522(b), (c), and (d) of the Pennsylvania Business Corporation Law of 1988, as amended (the “PBCL”), does hereby cer |
|
| August 21, 2023 |
Form of Series E Pre-funded Warrant. Exhibit 4.1 Exhibit A-2 SERIES E PREFUNDED COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: August 21, 2023 THIS SERIES E PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Baudax Bio, Inc. |
|
| August 21, 2023 |
Exhibit 4.2 Exhibit A-1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC |
|
| August 21, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Baudax Bio, Inc. |
|
| August 21, 2023 |
Form of Securities Purchase Agreement, by and Baudax Bio, Inc. and the purchasers party thereto. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 16, 2023, between Baudax Bio, Inc., a Pennsylvania corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| August 18, 2023 |
2,006,544 Shares of Common Stock and 1,395,243 Series E Pre-Funded Warrants to Purchase 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253117 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2021) 2,006,544 Shares of Common Stock and 1,395,243 Series E Pre-Funded Warrants to Purchase We are offering 2,006,544 shares of our common stock, par value $0.01 per share, directly to institutional investors. We are also offering 1,395,243 pre-funded warra |
|
| August 17, 2023 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333- 271161 Series A-5 Warrants to Purchase 3,478,262 Shares of Common Stock and Series A-6 Warrants to Purchase 3,478,262 Shares of Common Stock (and 6,956,524 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated August 17, 2023 (the “Supplement”), filed by Baudax Bio, Inc. (the “Company”), modifi |
|
| August 16, 2023 |
Exhibit 10.6 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. EXCLUSIVE LICENSE AGREEMENT BETWEEN THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. AND TERAIMMUNE, INC. THIS EXCLUSIVE LICENSE |
|
| August 16, 2023 |
Exhibit 10.5 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. L-188-2020 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U. |
|
| August 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Baudax Bio, Inc. |
|
| August 16, 2023 |
Exhibit 10.7 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. EXCLUSIVE LICENSE AGREEMENT BETWEEN THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. AND TERAIMMUNE, INC. THIS EXCLUSIVE LICENSE |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended: June 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-39101 Baudax Bio, Inc. (Exact name of registrant as specified i |
|
| August 16, 2023 |
Exhibit 99.1 Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace Announcement of Positive Top-Line Results from Phase 2 BX1000 Trial MALVERN, Pa., August 16, 2 |
|
| August 16, 2023 |
Exhibit 10.8 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. PUBLIC HEALTH SERVICE BIOLOGICAL MATERIALS LICENSE AGREEMENT This Agreement is based on the model Biological Material License Agreement adopted by the U.S. Pub |
|
| August 15, 2023 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (CHECK ONE): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR Commission File Number: 001-39101 For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Rep |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| August 9, 2023 |
Exhibit 99.1 DESCRIPTION OF BUSINESS OF BAUDAX BIO, INC. Exhibit 99.1 DESCRIPTION OF BUSINESS OF BAUDAX BIO, INC. Company Overview Baudax Bio, Inc. is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent. Our TCR Treg programs primarily focus on immune modulating therapi |
|
| August 9, 2023 |
Exhibit 99.2 RISK FACTOR SUMMARY The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section contained herein, as well as the Risk Factors sections found in our Annual Reports on Form 10-K, subsequent repor |
|
| August 9, 2023 |
Exhibit 99.1 DESCRIPTION OF BUSINESS OF BAUDAX BIO, INC. Exhibit 99.1 DESCRIPTION OF BUSINESS OF BAUDAX BIO, INC. Company Overview Baudax Bio, Inc. is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent. Our TCR Treg programs primarily focus on immune modulating therapi |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| August 9, 2023 |
Exhibit 99.2 RISK FACTOR SUMMARY The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section contained herein, as well as the Risk Factors sections found in our Annual Reports on Form 10-K, subsequent repor |
|
| July 31, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Conf |
|
| July 31, 2023 |
AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT AND AMENDMENT NO. 6 TO CREDIT AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT AND AMENDMENT NO. 6 TO CREDIT AGREEMENT This Amendment No. 1 to Forbearance Agreement and Amendment No. 6 to Credit Agreement (this “Amendment”) dated as of July 30, 2023, is among Baudax Bio, Inc., a Pennsylvania corporation (“Borrower”), Baudax Bio N.A. LLC, a Delaware limited liability company (“Baudax LLC”), Baudax Bio Limited, a private co |
|
| July 31, 2023 |
Exhibit 10.1 AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT AND AMENDMENT NO. 6 TO CREDIT AGREEMENT This Amendment No. 1 to Forbearance Agreement and Amendment No. 6 to Credit Agreement (this “Amendment”) dated as of July 30, 2023, is among Baudax Bio, Inc., a Pennsylvania corporation (“Borrower”), Baudax Bio N.A. LLC, a Delaware limited liability company (“Baudax LLC”), Baudax Bio Limited, a private co |
|
| July 31, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| July 31, 2023 |
false0001780097NASDAQ00017800972023-06-292023-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Baudax Bio, Inc. |
|
| July 25, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Baudax Bio, Inc. |
|
| July 17, 2023 |
EX-99.1 Overview Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: uses of proceeds; projected cash runways; future product development plans; and stockholder approval of the conversion rights of the Series X Preferred Stock, i |
|
| July 17, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 Baudax Bio, Inc. |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 Baudax Bio, Inc. |
|
| July 10, 2023 |
US07160F4046 / BAUDAX BIO INC / BLACK HORSE CAPITAL LP Passive Investment 12450867.1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Baudax Bio Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 07160F404 (CUSIP Number) June 30, 2023 (Date of Event whic |
|
| July 5, 2023 |
EX-10.1 Exhibit 10.1 Execution Version FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”), dated as of June 29, 2023 (the “Effective Date”), is made by and among Baudax Bio, Inc., a Pennsylvania corporation (“Borrower”), Baudax Bio N.A. LLC, a Delaware limited liability company (“Baudax LLC”), Baudax Bio Limited, a |
|
| July 5, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Baudax Bio, Inc. |
|
| July 5, 2023 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: BAUDAX BIO, INC., BOUNCE MERGER SUB I, INC., BOUNCE MERGER SUB II, LLC, and TERAIMMUNE, INC. Dated as of June 29, 2023 TABLE OF CONTENTS Page Section 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 3 1.3 Closing; First Effective Time; Second Effective Time 3 1.4 Certificate of Designation; Certifica |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Baudax Bio, Inc. |
|
| July 5, 2023 |
Certificate of Designations of Series X Non-Voting Convertible Preferred Stock. EX-3.1 Exhibit 3.1 BAUDAX BIO, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 1522 of the Pennsylvania Business Corporation Law of 1988 THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Baudax Bio, Inc., a Pennsylvania corporation (the “Corporation”), that the following resolution was duly adopted by the |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 Baudax Bio, Inc. |
|
| June 28, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 28, 2023 Registration No. |
|
| June 28, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Baudax Bio, Inc. |
|
| June 28, 2023 |
Exhibit 99.1 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this Exhibit 99.1. In addition to historical information, this discussion and analysis co |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Baudax Bio, Inc. |
|
| June 15, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Baudax Bio, Inc. |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 19, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Baudax Bio, Inc. |
|
| May 12, 2023 |
EX-99.1 Exhibit 99.1 Baudax Bio Reports First Quarter Financial Results and Provides Business Update Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio Secured $4 Million in Gross Proceeds from Public Offering in May MALVERN, Pa., May 12, 2023 (GLOBE |
|
| May 12, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 Baudax Bio, Inc. |
|
| May 11, 2023 |
Employment Agreement, by and between Baudax Bio, Inc. and Jillian Dilmore, dated May 10, 2023 Exhibit 10.4 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Baudax Bio, Inc. (the “Company”) and Jillian Dilmore (the “Executive”), on May 10, 2023, effective as of March 31, 2023 (the “Effective Date”). BACKGROUND WHEREAS, the Company desires to continue to employ the Executive, and the Executive desires to continue employment with the Com |
|
| May 11, 2023 |
Second Amended and Restated Bylaws of Baudax Bio, Inc. Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF BAUDAX BIO, INC. ARTICLE I OFFICES 1.1 Registered Office. The registered office of Baudax Bio, Inc. (the “Corporation”) shall be located within the Commonwealth of Pennsylvania at such place as the Board of Directors (the “Board of Directors” or the “Board”) shall determine from time to time. 1.2 Other Offices. The Corporation may also have such ot |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended: March 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-39101 Baudax Bio, Inc. (Exact name of registrant as specified |
|
| May 10, 2023 |
BAUDAX BIO Corporate Presentation May 2023 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Baudax Bio, Inc. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 Baudax Bio, Inc. |
|
| April 28, 2023 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-271161 1,326,175 Shares of Common Stock and accompanying Series A-5 Warrants to Purchase 1,326,175 Shares of Common Stock and Series A-6 Warrants to Purchase 1,326,175 Shares of Common Stock and 2,152,087 Series D Pre-funded Warrants to Purchase 2,152,087 Shares of Common Stock and accompanying Series A-5 Warrants to Pur |
|
| April 26, 2023 |
Form of Series D Pre-Funded Warrant. EX-4.2 Exhibit 4.2 SERIES D PREFUNDED COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS SERIES D PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| April 26, 2023 |
Baudax Bio, Inc. 490 Lapp Road Malvern, Pennsylvania 19355 April 26, 2023 CORRESP Baudax Bio, Inc. 490 Lapp Road Malvern, Pennsylvania 19355 April 26, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.C. 20549 Attn: Jane Park and Celeste Murphy Re: Baudax Bio, Inc. Registration Statement on Form S-1 SEC File No. 333-271161 Request for Acceleration Ms. Park: |
|
| April 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Baudax Bio, Inc. |
|
| April 26, 2023 |
Form of Placement Agent Warrant. EX-4.3 Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| April 26, 2023 |
EX-4.1 Exhibit 4.1 SERIES [A-5] [A-6] COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS SERIES [A-5] [A-6] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| April 26, 2023 |
EX-10.35 Exhibit 10.35 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Baudax Bio, Inc., a Pennsylvania corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| April 26, 2023 |
CORRESP Goodwin Procter LLP 2929 Arch Street Suite #1700 Philadelphia, Pennsylvania 19104 goodwinlaw. |
|
| April 26, 2023 |
CORRESP April 26, 2023 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Baudax Bio, Inc. Registration Statement on Form S-1 (Registration No. 333-271161)— Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pu |
|
| April 26, 2023 |
As filed with the Securities and Exchange Commission on April 26, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on April 26, 2023 Registration No. |
|
| April 25, 2023 |
EX-99.2 3 d423289dex992.htm EX-99.2 Exhibit 99.2 Study BDX-22-006 Top Line Results 25 April 2023 Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements, including statements relating to the clinical development of Baudax Bio’s product candidates, reflect Baudax Bio’s expectations about its future perfor |
|
| April 25, 2023 |
EX-99.1 2 d423289dex991.htm EX-99.1 Exhibit 99.1 Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000 All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions at 60 Seconds Results to be Discussed in Key Opinion Leader Webinar Today at 10:00am Eastern Time MALVERN, Pa., April 25, 2022 (GLOBE NEWSWIRE) — |
|
| April 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Baudax Bio, Inc. |
|
| April 6, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Baudax Bio, Inc. |
|
| April 6, 2023 |
As filed with the Securities and Exchange Commission on April 6, 2023 S-1 Table of Contents As filed with the Securities and Exchange Commission on April 6, 2023 Registration No. |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| April 4, 2023 |
EX-10.3 2 d460062dex103.htm EX-10.3 Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. ASSET TRANSFER AGREEMENT among ALKERMES PHARMA IRELAND LIMITED as Purchaser and BAUDAX BIO, INC. as Seller Dated as of March 29, 2023 CERTAIN CONFIDE |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Baudax Bio, Inc. |
|
| March 31, 2023 |
EX-10.1 Exhibit 10.1 AMENDMENT NO. 5 AND CONSENT TO CREDIT AGREEMENT This Amendment No. 5 and Consent to Credit Agreement (this “Amendment”) dated as of March 29, 2023, is among Baudax Bio, Inc., a Pennsylvania corporation (“Borrower”), Baudax Bio N.A. LLC, a Delaware limited liability company (“Baudax LLC”), Baudax Bio Limited, a private company incorporated under the laws of Ireland limited by s |
|
| March 31, 2023 |
Common Stock Purchase Warrant, dated March 29, 2023, in favor of MAM Eagle Lender, LLC. EX-4.1 2 d454236dex41.htm EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SECURITIES PURCHASABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION F |
|
| March 31, 2023 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 29, 2023, is entered into by and between Baudax Bio, Inc., a company organized under the laws of the Commonwealth of Pennsylvania (the “Company”), and MAM Eagle Lender, LLC (the “Initial Holder”). R E C I T A L S WHEREAS, on or about the date hereof, the Company issued to the |
|
| March 27, 2023 |
EX-99.1 Exhibit 99.1 March 27, 2023 Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000 41 Subjects Meet Criteria for Good or Excellent Intubation Conditions at 60 Seconds Top Line Results Expected Late April/Early May MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused o |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Baudax Bio, Inc. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Baudax Bio, Inc. |
|
| March 3, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Baudax Bio, Inc. |
|
| March 3, 2023 |
EX-99.1 2 d446208dex991.htm EX-99.1 Exhibit 99.1 BAUDAX BIO Corporate Presentation March 2023 Confidential: For Internal Use Only I Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and u |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39101 Baudax Bio, Inc |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 S-8 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Baudax Bio, Inc. |
|
| February 23, 2023 |
EX-99.1 Exhibit 99.1 Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update Company Focuses on Development of Neuromuscular Blocking Agents; Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1 2023, Top Line Results Expected Early Q2 2023 BX2000 Dose Escalation Study Progressing $5 |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Baudax Bio, Inc. |
|
| February 23, 2023 |
EX-10 2 bxrx-ex1038.htm EX-10.38 Exhibit 10.38 AMENDMENT NO. 4 TO CREDIT AGREEMENT This Amendment No. 4 to Credit Agreement (this “Amendment”) dated as of January 5, 2023, is among Baudax Bio, Inc., a Pennsylvania corporation (“Borrower”), Baudax Bio N.A. LLC, a Delaware limited liability company (“Baudax LLC”), Baudax Bio Limited, a private company incorporated under the laws of Ireland limited b |
|
| February 14, 2023 |
US07160F4046 / BAUDAX BIO INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Baudax Bio, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 07160F404 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 24, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Baudax Bio, Inc. |
|
| January 24, 2023 |
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000 Exhibit 99.1 Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000 MALVERN, Pa., January 24, 2023 — Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Baudax Bio, Inc. |
|
| January 9, 2023 |
Baudax Bio Corporate Presentation January 2023 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “esti |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 Baudax Bio, Inc. |
|
| December 6, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-243488 Warrants to Purchase 7,358 Shares of Common Stock (and up to 7,358 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated December 2, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, dat |
|
| December 6, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-253117 Warrants to Purchase 90,567 Shares of Common Stock (and up to 90,567 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated December 2, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, d |
|
| December 6, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-243488 Warrants to Purchase 7,234 Shares of Common Stock (and up to 7,234 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated December 2, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, dat |
|
| December 6, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333- 253117 Warrants to Purchase 9,063 Shares of Common Stock (and up to 9,063 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated December 2, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, da |
|
| December 6, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333- 266499 Series A-1 Warrants to Purchase 295,480 Shares of Common Stock and Series A-2 Warrants to Purchase 295,480 Shares of Common Stock (and up to 590,958 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated December 2, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and su |
|
| December 6, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-235408 Warrants to Purchase 10,021 Shares of Common Stock (and up to 10, 021 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated December 2, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, |
|
| December 5, 2022 |
Form of Warrant Amendment Agreement Exhibit 4.1 December 2, 2022 Holder of Warrants to Purchase Common Stock issued on (i) November 25, 2020, (ii) January 25, 2021, (iii) June 1, 2021, (iv) December 28, 2021, (v) March 1, 2022, (vi) May 19, 2022, (vii) September 1, 2022 and (viii) September 1, 2022 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form S-1 (File No. 333-268251) on or about t |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 Baudax Bio, Inc. |
|
| December 5, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333- 268251 54,787 Shares of Common Stock and accompanying Series A-3 Warrants to Purchase 54,787 Shares of Common Stock and Series A-4 Warrants to Purchase 54,787 Shares of Common Stock and 988,000 Series C Pre-funded Warrants to Purchase 988,000 Shares of Common Stock and accompanying Series A-3 Warrants to Purchase 988,000 Shar |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Baudax Bio, Inc. |
|
| December 1, 2022 |
Baudax Bio, Inc. 490 Lapp Road Malvern, Pennsylvania 19355 December 1, 2022 Baudax Bio, Inc. 490 Lapp Road Malvern, Pennsylvania 19355 December 1, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Benjamin Richie and Dorrie Yale Re: Baudax Bio, Inc. Registration Statement on Form S-1 SEC File No. 333-268251 Request for Acceleration Mr. Richie: Pursuant to Rule 461 of |
|
| December 1, 2022 |
Exhibit 10.1 AMENDMENT NO. 3 TO CREDIT AGREEMENT This Amendment No. 3 to Credit Agreement (this ?Amendment?) effective as of November 30, 2022 and executed on December 1, 2022, is among Baudax Bio, Inc., a Pennsylvania corporation (?Borrower?), Baudax Bio N.A. LLC, a Delaware limited liability company (?Baudax LLC?), Baudax Bio Limited, a private company incorporated under the laws of Ireland limi |
|
| December 1, 2022 |
As filed with the Securities and Exchange Commission on December 1, 2022 S-1/A 1 d415436ds1a.htm S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 1, 2022 Registration No. 333-268251 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 3) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Baudax Bio, Inc. (Exact name of Registrant as specified in its charter) Pennsylvania 8090 47-463 |
|
| December 1, 2022 |
430 Park Avenue | New York, NY 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC December 1, 2022 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Baudax Bio, Inc. Registration Statement on Form S-1 (Registration No. 333-268251) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (?Wainwright?), solely acting as placement agent on a best-efforts basis in an offering pursuan |
|
| November 30, 2022 |
As filed with the Securities and Exchange Commission on November 30, 2022 S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 30, 2022 Registration No. |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 Baudax Bio, Inc. |
|
| November 30, 2022 |
Troutman Pepper Hamilton Sanders LLP 3000 Two Logan Square, Eighteenth and Arch Streets Philadelphia, PA 19103-2799 troutman. |
|
| November 30, 2022 |
EX-3.1 Exhibit 3.1 ARTICLES OF AMENDMENT OF BAUDAX BIO, INC. In compliance with the requirements of the applicable provisions (relating to articles of amendment) of the Pennsylvania Business Corporation Law of 1988, as amended, the undersigned, desiring to amend its Amended and Restated Articles of Incorporation, hereby states that: 1. The name of the Corporation is Baudax Bio, Inc. (the “Corporat |
|
| November 28, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Baudax Bio, Inc. |
|
| November 28, 2022 |
EX-10.35 Exhibit 10.35 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2022, between Baudax Bio, Inc., a Pennsylvania corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| November 28, 2022 |
Troutman Pepper Hamilton Sanders LLP 3000 Two Logan Square, Eighteenth and Arch Streets Philadelphia, PA 19103-2799 troutman. |
|
| November 28, 2022 |
Form of Placement Agent Warrant EX-4.3 Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| November 28, 2022 |
Form of Series C Pre-Funded Warrant EX-4.2 Exhibit 4.2 SERIES C PREFUNDED COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: November , 2022 THIS SERIES C PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| November 28, 2022 |
EX-4.1 Exhibit 4.1 SERIES [A-3] [A-4] COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES [A-3] [A-4] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| November 28, 2022 |
As filed with the Securities and Exchange Commission on November 28, 2022 S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 28, 2022 Registration No. |
|
| November 18, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 Baudax Bio, Inc. |
|
| November 8, 2022 |
EX-99.1 Exhibit 99.1 Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights BX 1000 Phase II Trial Underway BX 2000 Dose Escalation Study Progressing ANJESO® Vials Sold to End Users Up 16% Third Quarter Year-Over-Year USPTO Issues Note of Allowance for additional Orange Book Listable ANJESO® Patent MALVERN, Pa., Nov. 8, 2022 (GLOBE NEWSWIRE)— Baudax Bio, Inc. (NASDAQ:BXRX) |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Baudax Bio, Inc. |
|
| November 8, 2022 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on November 8, 2022 Registration No. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended: September 30, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-39101 Baudax Bio, Inc. (Exact name of registrant as specif |
|
| November 8, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Baudax Bio, Inc. |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Baudax Bio, Inc. |
|
| October 28, 2022 |
Exhibit 10.1 Execution Copy AMENDMENT NO. 2 TO CREDIT AGREEMENT This Amendment No. 2 to Credit Agreement (this ?Amendment?) dated as of October 24, 2022, is among Baudax Bio, Inc., a Pennsylvania corporation (?Borrower?), Baudax Bio N.A. LLC, a Delaware limited liability company (?Baudax LLC?), Baudax Bio Limited, a private company incorporated under the laws of Ireland limited by shares having co |
|
| October 13, 2022 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| September 21, 2022 |
Exhibit 3.1 BAUDAX BIO, INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK OF BAUDAX BIO, INC. SEPTEMBER 20, 2022 Baudax Bio, Inc., a corporation organized and existing under the laws of the Commonwealth of Pennsylvania (the ?Corporation?), in accordance with the provisions of 1522(b), (c), and (d) of the Pennsylvania Business Corporation Law of 1988, as amended (the ?PBCL?), does hereby |
|
| September 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-A For Registration of Certain Classes of Securities Pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934 Baudax Bio, Inc. |
|
| September 20, 2022 |
Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock. Exhibit 3.1 BAUDAX BIO, INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK OF BAUDAX BIO, INC. SEPTEMBER 20, 2022 Baudax Bio, Inc., a corporation organized and existing under the laws of the Commonwealth of Pennsylvania (the ?Corporation?), in accordance with the provisions of 1522(b), (c), and (d) of the Pennsylvania Business Corporation Law of 1988, as amended (the ?PBCL?), does hereby |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Baudax Bio, Inc. |
|
| September 6, 2022 |
BXRX / Baudax Bio Inc / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Baudax Bio, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 07160F107 (CUSIP Number) August 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| September 6, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| August 31, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-266499 PROSPECTUS $6,162,422.44 7,554,886 Shares of Common Stock and accompanying Series A-1 Warrants to Purchase 7,554,886 Shares of Common Stock and Series A-2 Warrants to Purchase 7,554,886 Shares of Common Stock 4,264,286 Series B Pre-funded Warrants to Purchase 4,264,286 Shares of Common Stock and accompanying Series A-1 |
|
| August 31, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2022 Baudax Bio, Inc. |
|
| August 25, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-235408 Warrants to Purchase 400,815 Shares of Common Stock (and up to 400,815 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated August 24, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, |
|
| August 25, 2022 |
Form of Warrant Amendment Agreement Exhibit 4.1 August 24, 2022 Holder of Warrants to Purchase Common Stock issued on [ ] Re: Amendment to Existing Warrants Dear Holder: This letter confirms that Baudax Bio, Inc. (the ?Company?) hereby amends, effective as of the date hereof, the Holder?s existing warrants to purchase up to shares of common Stock at an exercise price of $[ ] per share issued on [ ] (collectively, the ?Existing Warra |
|
| August 25, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-243488 Warrants to Purchase 289,331 Shares of Common Stock (and up to 289,331 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated August 24, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, |
|
| August 25, 2022 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 Baudax Bio, Inc. |
|
| August 25, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333- 253117 Warrants to Purchase 362,479 Shares of Common Stock (and up to 362,479 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated August 24, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, |
|
| August 25, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-243488 Warrants to Purchase 294,298 Shares of Common Stock (and up to 294,298 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated August 24, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus supplement, |
|
| August 25, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-243488 Warrants to Purchase 3,622,668 Shares of Common Stock (and up to 3,622,668 Shares of Common Stock Issuable Upon Exercise of Such Warrants) This prospectus supplement, dated August 24, 2022 (?Supplement?), filed by Baudax Bio, Inc. (the ?Company?), modifies and supplements certain information contained in the Company?s prospectus suppleme |
|
| August 24, 2022 |
August 24, 2022 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Baudax Bio, Inc. Registration Statement on Form S-1 (Registration No. 333-266499) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (?Wainwright?), solely acting as placement agent on a best-efforts basis in an offering pursuant |
|
| August 24, 2022 |
Baudax Bio, Inc. 490 Lapp Road Malvern, Pennsylvania 19355 August 24, 2022 Baudax Bio, Inc. 490 Lapp Road Malvern, Pennsylvania 19355 August 24, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Daniel Crawford Re: Baudax Bio, Inc. Registration Statement on Form S-1 SEC File No. 333-266499 Request for Acceleration Mr. Crawford: Pursuant to Rule 461 of Regulation C o |
|
| August 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 Baudax Bio, Inc. |
|
| August 23, 2022 |
Exhibit 99.1 Baudax Bio Corporate Presentation August 2022 Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect BaudaxBio?s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words?anticipate,??believe,??estimate, |
|
| August 17, 2022 |
EXHIBIT 10.35 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2022, between Baudax Bio, Inc., a Pennsylvania corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth |
|
| August 17, 2022 |
Exhibit 4.20 SERIES A-1 COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES A-1 COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth |
|
| August 17, 2022 |
Form of Series B Pre-Funded Warrant Exhibit 4.22 SERIES B PREFUNDED COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES B PREFUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| August 17, 2022 |
Exhibit 4.21 SERIES A-2 COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES A-2 COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth |
|
| August 17, 2022 |
Form of Placement Agent Warrant Exhibit 4.23 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| August 17, 2022 |
As filed with the Securities and Exchange Commission on August 16, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 16, 2022 Registration No. |
|
| August 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Baudax Bio, Inc. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended: June 30, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-39101 Baudax Bio, Inc. (Exact name of registrant as specified i |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Baudax Bio, Inc. |
|
| August 11, 2022 |
EX-99.1 Exhibit 99.1 Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I BX2000 Study; On Track to Complete Enrollment in Remaining Cohorts by Early 2023 MALVERN, Pa., August 11, 2022 — Baudax Bio, Inc. (NASDAQ:BXRX) (the “ |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Baudax Bio, Inc. |
|
| August 3, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Baudax Bio, Inc. |
|
| August 3, 2022 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. AMENDMENT NO. 1 AND WAIVER TO CREDIT AGREEMENT This Amendment No. 1 and Waiver to Credit Agreement (this ?Amendment?) dated as of August 1, 2022, is among Baud |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. |
|
| July 8, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2022 Baudax Bio, Inc. |
|
| June 27, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 Baudax Bio, Inc. |
|
| June 27, 2022 |
Exhibit 16.1 KPMG LLP June 27, 2022 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Baudax Bio, Inc. (the Company) and, under the date of March 16, 2022, we reported on the consolidated financial statements of Baudax Bio, Inc. as of and for the years ended December 31, 2021 and 2020. On June 21, 2022, we were dismissed. W |
|
| May 27, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| May 27, 2022 |
BXRX / Baudax Bio Inc / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Baudax Bio, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 07160F107 (CUSIP Number) May 17, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| May 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 Baudax Bio, Inc. |
|
| May 19, 2022 |
1,646,091 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253117 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2021) 1,646,091 Shares of Common Stock We are offering 1,646,091 shares of our common stock, par value $0.01 per share, directly to institutional investors. In a concurrent private placement, we are also selling, to the purchasers of shares of our common stock in t |
|
| May 18, 2022 |
Form of Placement Agent Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 18, 2022 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of May 17, 2022, between Baudax Bio, Inc., a Pennsylvania corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set |
|
| May 18, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 Baudax Bio, Inc. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended: March 31, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-39101 Baudax Bio, Inc. (Exact name of registrant as specified |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Baudax Bio, Inc. |
|
| May 5, 2022 |
Exhibit 99.2 May 5, 2022 1 This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio?s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words ?anticipate,? ?believe,? ?estimate,? ?may,? ?upcoming,? ?plan,? ?target,? ?goal,? ?intend, |
|
| May 5, 2022 |
Exhibit 99.1 Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights ANJESO? Net Product Revenue Up 113% Compared to Same Period in Prior Year; Sixth Consecutive Quarter of Demand Growth First Cohort Dosed in Pediatric ANJESO Surgical Study Management to Host Investor Conference Call and Webcast Tomorrow at 8:30 a.m. ET MALVERN, Pa., May 4, 2022 ? Baudax Bio, Inc. (NASDAQ:B |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Baudax Bio, Inc. |
|
| April 20, 2022 |
Exhibit 99.1 Baudax Bio Noblecon18 Presentation th April 20 , 2022 Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect BaudaxBio?s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words ?anticipate,??believe,?? |
|
| April 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 Baudax Bio, Inc. |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 Baudax Bio, Inc. |
|
| March 31, 2022 |
DEF 14A 1 bxrx-def14a20220504.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| March 16, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Baudax Bio, Inc. |
|
| March 16, 2022 |
EX-4.18 3 bxrx-ex418.htm EX-4.18 Exhibit 4.18 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Baudax Bio, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company’s common stock, par value $0.01 per share (“Common Stock”) is re |
|
| March 16, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Baudax Bio, Inc. |
|
| March 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 Baudax Bio, Inc. |
|
| March 16, 2022 |
Form of Warrant, issued June 1, 2021. Exhibit 4.11 COMMON STOCK PURCHASE WARRANT Baudax Bio, Inc. Warrant Shares: Issue Date: June 1, 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the later of (a) the six-month anniversary of |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39101 Baudax Bio, Inc |
|
| March 16, 2022 |
Power of Attorney (included in signature page to this Registration Statement) As filed with the Securities and Exchange Commission on March 16, 2022 Registration No. |
|
| March 16, 2022 |
As filed with the Securities and Exchange Commission on March 16, 2022 As filed with the Securities and Exchange Commission on March 16, 2022 Registration No. |
|
| March 16, 2022 |
Exhibit 99.1 Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results ANJESO End User Demand and Revenue Increases Four Quarters In A Row Neuromuscular Blocking Agents Advancing MALVERN, Pa., March 16, 2022 - Baudax Bio, Inc. (NASDAQ:BXRX) (the ?Company?), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today reported finan |
|
| March 7, 2022 |
Baudax Bio Regains Compliance with NASDAQ Listing Requirements Exhibit 99.1 Baudax Bio Regains Compliance with NASDAQ Listing Requirements MALVERN, Pa., March 7, 2022 ? Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced that the Company received a letter on March 3, 2022 from The Nasdaq Stock Market noting the Company has regained compliance with the minimum |
|
| March 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 Baudax Bio, Inc. |
|
| March 2, 2022 |
Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO Exhibit 99.1 Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO? MALVERN, Pa., March 02, 2022 (GLOBE NEWSWIRE) ? Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that it has secured the issuance of United States Patent No.11,253,478 (the ?478 Patent). The ?478 Patent cove |
|
| March 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 Baudax Bio, Inc. |
|
| March 1, 2022 |
Form of Investor Warrant, issued March 1, 2022. Exhibit 4.1 UNDERWRITER COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: March 1, 2022 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after March 1, 2 |
|
| March 1, 2022 |
Form of Pre-Funded Warrant, issued March 1, 2022. Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: March 1, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after March 1, 202 |
|
| March 1, 2022 |
Form of Underwriter Warrant, issued March 1, 2022. Exhibit 4.3 COMMON STOCK PURCHASE WARRANT BAUDAX BIO, INC. Warrant Shares: Initial Exercise Date: March 1, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after March 1, 2022 (the ?Initial Exerci |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Baudax Bio, Inc. |
|
| March 1, 2022 |
Exhibit 1.1 1,831,631 Shares Pre-Funded Warrants to Purchase 1,677,141 Shares Common Warrants to Purchase 3,508,772 Shares BAUDAX BIO, INC. UNDERWRITING AGREEMENT February 24, 2022 H.C. Wainwright & Co., LLC As representative of the underwriters named in Schedule I hereto c/o H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Baudax Bio, Inc., a Pennsylvania |
|
| February 28, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253117 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2021) 1,831,631 Shares of Common Stock Common Warrants to Purchase up to 3,508,772 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,677,141 Shares of Common Stock Representative Warrants to Purchase up to 210,526 Shares of Common Stock (and the Shares |
|
| February 24, 2022 |
Subject to completion, dated February 24, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253117 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not offers to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitt |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 Baudax Bio, Inc. |
|
| February 15, 2022 |
Articles of Amendment to the Amended and Restated Articles of Incorporation of Baudax Bio, Inc. EX-3.1 2 d473889dex31.htm EX-3.1 Exhibit 3.1 ARTICLES OF AMENDMENT OF BAUDAX BIO, INC. In compliance with the requirements of the applicable provisions (relating to articles of amendment) of the Pennsylvania Business Corporation Law of 1988, as amended, the undersigned, desiring to amend its Amended and Restated Articles of Incorporation, hereby states that: 1. The name of the Corporation is Bauda |
|
| February 15, 2022 |
EX-99.A 2 d308782dex99a.htm EX-99.A Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.01, of Baudax Bio, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 15, 2022 |
BXRX / Baudax Bio Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 Baudax Bio, Inc. |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| January 6, 2022 |
BXRX / Baudax Bio Inc / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Baudax Bio, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 07160F107 (CUSIP Number) December 27, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 Baudax Bio, Inc. |
|
| January 4, 2022 |
Exhibit 99.1 Baudax Bio Corporate Presentation January 2022 1 Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio?s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words ?anticipate,? ?believe,? ?es |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 28, 2021 |
EX-3.1 2 d277623dex31.htm EX-3.1 Exhibit 3.1 BAUDAX BIO, INC. CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF BAUDAX BIO, INC. DECEMBER 28, 2021 Baudax Bio, Inc., a corporation organized and existing under the laws of the Commonwealth of Pennsylvania (the “Corporation”), in accordance with the provisions of 1522(b), (c), and (d) of the Pennsylvania Business Corporation Law of |
|
| December 28, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253117 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2021) 42,289.3 Shares of Series A Convertible Preferred Stock Warrants to purchase up to 12,686,790 Shares of Common Stock Placement Agent Warrants to Purchase up to 1,014,943 Shares of Common Stock (and 30,617,453 Shares of Common Stock issuable upon the conversio |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2021 Baudax Bio, Inc. |
